Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Registers Shares for Selling Stockholders

NEW YORK (GenomeWeb News) – Helicos BioSciences has filed a prospectus with the US Securities and Exchange Commission on behalf of selling shareholders offering around 6.6 million shares of the firm's common stock.

The firm will offer the resale from time to time of up to 6,633,789 shares of its common stock, with 2,322,509 of those shares issuable upon exercise of warrants. Helicos is not selling any securities in the offering and will not receive any of the proceeds from the selling shareholders.

The total shares of common stock being offered, including the warrants, is the same number of shares that the firm recently issued in a private placement that netted Helicos $9.4 million in proceeds.

Among the investors in that private placement that are also listed in the prospectus as potential selling shareholders are Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures, and the firm's CEO, Ron Lowy. Also listed in the prospectus as potential sellers are other investors including Empery Asset Management, Capital Ventures International, Hudson Bay, RA Capital Healthcare Fund, and Ramius.

Helicos notes in the prospectus that the selling shareholders may "sell some, all or none of their shares."

In early Thursday trade on the Nasdaq, Helicos' shares were down 2 percent at $2.81.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more